Bioiberica’s Collavant n2 combined with Boswellia serrata reduces osteoarthritis symptoms, study finds

21 Jun 2022 --- Life science company Bioiberica’s native type II collagen – Collavant n2 – in combination with the herbal extract Boswellia serrata was found to reduce osteoarthritis symptoms in five days.

This is according to an India-based study that will further opportunities for nutraceutical manufacturers to bring holistic solutions to the growing mobility market that combines on-trend ingredients.

“Boswellia serrata is considered a potent anti-inflammatory and anti-arthritic herbal extract that may help improve pain and physical function in patients with osteoarthritis. Likewise, Collavant n2 has demonstrated benefits in joint health at only 40 mg per day,” details Daniel Martínez Puig, head of R&D human health at Bioiberica.

“This makes both ingredients attractive options for innovation in the mobility space.”

 “These findings present an opportunity for formulators looking to explore new combinations with trending ingredients, like native type II collagen and herbal extracts and show the potential to unlock solutions that deliver novel benefits,” he adds.

Osteoarthritis is a degenerative joint disorder that is the leading cause of pain in the joint health space.

Spotlight on Collavant n2
Collavant n2, extracted from the chicken sternum and created in a strictly controlled process, is a low-dose supplement that helps maintain healthy joints and, as a result, overall quality of life. 

“Usually, when used alone, the benefits of Collavant n2 are experienced within one to two months, so we were interested when our strategic partner in India shared the results of this study with us, showing that when used in combination with this herbal extract, the benefits were felt in five days,” Puig explains.

The collagen and Boswellia serrata combination was effective at reducing pain associated with knee osteoarthritis (Credit: Bioiberica).“This signifies that specific ingredients can bring advantages, like enhanced efficacy, when brought together in one solution.”

As revealed in the observational research, native type II collagen provides increased flexibility and compatibility with other joint health ingredients, making it easier for formulators to innovate in the sector.

Analyzing pain scores for knee osteoarthritis
The multicentric clinical research, which enrolled 40 patients, was designed to determine the efficacy and safety of a proprietary Boswellia serrata extract in conjunction with Collavant n2 native type II collagen for people suffering from osteoarthritis knee pain.

The solution (40 mg Collavant n2 and 100 mg Boswellia serrata) was given orally daily for three months.

From day five of the research, a “significant reduction” in VAS (visual analog scale) was seen, demonstrating that the collagen and Boswellia serrata combination was quick and effective at reducing pain associated with knee osteoarthritis.

The findings revealed pain scores decreased over time, as measured on days 15, 30, 60 and 90, showing Collavant n2’s long-term benefit in promoting joint health. 

Compared to the baseline, patients reported less stiffness and improved physical function. No severe side effects were reported, indicating that the solution is well-tolerated and safe.

Collagen and herbal blends emerge
Puig adds that the number of product launches featuring collagen and herbal combinations has grown at a CAGR of 25% since 2017.

Boswellia serrata is an anti-inflammatory herbal extract that may help improve pain.“Those [launches] containing native type II collagen and Boswellia serrata specifically have risen at a CAGR of 71% since 2018.”

Innova Market Insights’ data echoes the rise in joint health claims that feature collagen, with this space featuring an 85% increase in the last five years. Additionally, type II collagen “has emerged in new launches, particularly gaining popularity in combinations with other ingredients for joint health.”

Previous innovations for type II collagen and Boswellia extract
Earlier this year, Bioiberica delivered its native type II collagen to China’s expanding joint health market in partnership with ByHeath – a supplements provider.

NutritionInsight previously reported on the efficacy of PLT Health Solutions’ Boswellia extract, which was pegged as having efficacy “as fast as five days and with doses as low as 100 mg.”

Bioiberica rebranded its healthcare offering to match the evolving mobility market’s “continuous innovation.” The company rebranded its native (undenatured) type II collagen, Collavant n2 (previously b-2Cool).

By Nicole Kerr